Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ramucirumab plus paclitaxel for elderly patients with unresectable or metastatic gastric cancer (T-CORE1501)
jRCTs021180016Phase 2Completed
- Sponsor
- Tohoku Clinical Oncology Research and Educational Society
- Start
- May 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and paclitaxel in gastric adenocarcinoma, sponsored by Tohoku Clinical Oncology Research and Educational Society. Primary endpoint: Progression-free survival. Started May 2016; status: completed.
02
Drugs
ramucirumabpaclitaxel
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs021180016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180016.